SuperworthCitius Pharmaceuticals CTXR
- Market cap
- $11.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Citius Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $3.9M | $1.7M | $1.5M | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $789.2K | $328.9K | $491.8K |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $3.2M | $1.3M | $1M |
| R&D | $2.9M−25% | $2.6M−24% | $3.6M−24% | $2.8M−27% | $2.9M+1% | $2.1M−19% | $3.8M+5% | $1.6M−41% | $1.6M−44% | $1.6M−25% | $1.6M−57% | $1.1M−35% |
| SG&A | $4.2M+53% | $3.7M+41% | $4.3M−11% | $4.8M+29% | $5.5M+32% | $5.4M+47% | $4.8M+12% | $4.4M−8% | $3.9M−29% | $5.7M+6% | $26.4M+451% | $6.1M+38% |
| −$10.1M+34% | −$9.3M+29% | −$11M+3% | −$10.6M+23% | −$11.1M+9% | −$10M+8% | −$11.3M+3% | −$8.8M−17% | −$8.4M−24% | −$9M−10% | −$32.2M+186% | −$11.7M+34% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $172.3K | $95.5K | $155.5K | $33K | $231.7K+35% |
| Pre-tax income | −$9.8M+32% | −$9.1M+163% | −$8.4M−19% | −$10.4M+25% | −$10.9M+12% | −$10M+10% | −$11.2M+34% | −$8.9M−14% | −$8.5M−22% | −$9.1M−9% | −$28.3M+152% | −$12M+35% |
| $144K | $144K+0% | $144K+0% | $144K+0% | $144K+0% | $264.2K+84% | $264.2K+84% | $264.2K+84% | $264.2K+84% | $264.2K+0% | −$231.2K | −$107.3K | |
| Net income | −$9.9M+24% | −$9.2M+157% | −$8.5M−19% | −$10.6M+25% | −$10.8M+9% | −$9.8M+6% | −$10.9M+28% | −$8.8M−17% | −$8M−26% | −$8.2M−16% | −$21.2M+95% | −$8.9M+1% |
| −$0.07+40% | −$1.45+7150% | −$1.34+1814% | −$1.57+2517% | −$1.59+2171% | −$1.30−10% | −$1.27−5% | −$0.80−49% | −$0.46−71% | −$0.38−71% | −$0.95−25% | −$0.34−58% | |
| 158.9M+9% | 6.4M−96% | 6.4M−96% | 7M−96% | 7.2M−95% | 7.5M+18% | 8.6M+35% | 11M+58% | 17.1M+137% | 21.5M+187% | 22.4M+161% | 26.2M+138% |
EPS, diluted: 20 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q3 FY11: not printed by the filing, worked out from its own lines. 15 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Citius Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CTXRCitius Pharmaceuticals | $11.1M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Citius Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .